dr. smith on the rationale behind the fixed duration trial for ibrutinib/venetoclax in cll
Published 4 years ago • 314 plays • Length 1:31Download video MP4
Download video MP3
Similar videos
-
1:05
dr. smith on using venetoclax versus ibrutinib in cll
-
1:00
dr. smith on ibrutinib-based therapies in cll
-
1:51
dr. smith on frontline treatment considerations in cll
-
2:43
outcomes in high-risk cll patients following fixed-duration treatment with ibrutinib plus venetoclax
-
4:45
frontline ibrutinib venetoclax in cll: results from a fixed duration cohort of the captivate study
-
9:41
what is venetoclax? #aml
-
18:52
brcch | covid-19 – a systemic vasculo-inflammatory disease
-
8:57
venetoclax combined with obinutuzumab for untreated cll (chronic lymphocytic leukemia)
-
11:23
captivate: fixed-duration first-line treatment with ibrutinib plus venetoclax for cll/sll
-
29:14
ibrutinib resistance-mechanisms and options in cll
-
2:17
uk ncri flair trial: ibrutinib venetoclax with mrd-directed duration of treatment in cll
-
8:11
ibrutinib combined with venetoclax for cll treatment - 4-year follow-up
-
1:53
achieving undetectable mrd with ibrutinib plus venetoclax for cll
-
1:23
captivate: fixed-duration ibrutinib plus venetoclax in patients with cll/sll
-
2:12
dr. brander on the safety and efficacy of ibrutinib/venetoclax in cll
-
1:32
cll14: feasibility of fixed-duration frontline therapy in cll
-
1:23
interim analysis of the flair study: efficacy of ibrutinib plus venetoclax in ighv unmutated cll
-
6:39
ibrutinib venetoclax for chronic lymphocytic leukemia (cll) treatment - dr. bill wierda ash 2022
-
3:33
investigating the safety and efficacy of re-treating cll patients with venetoclax-based regimens
-
1:09
dr. byrd on long-term safety data with ibrutinib in cll
-
3:01
ibrutinib venetoclax for cll
-
4:44
7-year update on a phase ii trial of fixed-duration obinutuzumab, ibrutinib, and venetoclax for cll